Literature DB >> 10970702

Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome.

S A Julious1, M J Campbell, S J Walker, S L George, D Machin.   

Abstract

Health Related Quality of Life (HRQoL) instruments are increasingly important in evaluating health care, especially in cancer trials. When planning a trial, one essential step is the calculation of a sample size, which will allow a reasonable chance (power) of detecting a pre-specified difference (effect size) at a given level of statistical significance. It is almost mandatory to include this calculation in research protocols. Many researchers quote means and standard deviations to determine effect sizes, and assume the data will have a Normal distribution to calculate their required sample size. We have investigated the distribution of scores for two commonly used HRQoL instruments completed by lung cancer patients, and have established that scores do not have the Normal distribution form. We demonstrate that an assumption of Normality can lead to unrealistically sized studies. Our recommendation is to use a technique that is based on the fact that the HRQoL data are ordinal and makes minimal but realistic assumptions. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970702      PMCID: PMC2374670          DOI: 10.1054/bjoc.2000.1383

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer.

Authors:  S Moorey; S Greer; M Watson; C Gorman; L Rowden; R Tunmore; B Robertson; J Bliss
Journal:  Br J Psychiatry       Date:  1991-02       Impact factor: 9.319

2.  Sample sizes for randomized trials measuring quality of life in cancer patients.

Authors:  S A Julious; S George; D Machin; R J Stephens
Journal:  Qual Life Res       Date:  1997-03       Impact factor: 4.147

Review 3.  Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons.

Authors:  M J Campbell; S A Julious; D G Altman
Journal:  BMJ       Date:  1995-10-28

4.  Sample sizes for studies using the short form 36 (SF-36)

Authors:  S A Julious; S George; M J Campbell
Journal:  J Epidemiol Community Health       Date:  1995-12       Impact factor: 3.710

5.  Sample size calculations for ordered categorical data.

Authors:  J Whitehead
Journal:  Stat Med       Date:  1993-12-30       Impact factor: 2.373

Review 6.  The quality of life of cancer patients: a review of the literature.

Authors:  J C de Haes; F C van Knippenberg
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

7.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

8.  Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist.

Authors:  J C de Haes; F C van Knippenberg; J P Neijt
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

Review 9.  Sample size: how many patients are necessary?

Authors:  P M Fayers; D Machin
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  9 in total
  2 in total

1.  Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.

Authors:  David Cella; Robert J Motzer; Brian I Rini; Joseph C Cappelleri; Krishnan Ramaswamy; Subramanian Hariharan; Bhakti Arondekar; Andrew G Bushmakin
Journal:  Value Health       Date:  2018-05-11       Impact factor: 5.725

2.  Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocol.

Authors:  Caryn Chan Mei Hsien; Wan Azmad Wan Azman; Mastura Md Yusof; Gwo Fuang Ho; Edward Krupat
Journal:  BMJ Open       Date:  2012-10-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.